1255206-72-4

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-bromo-3-hydroxymethyl-2-methyl phenol is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Personal Care and Hygiene Products:
Due to its antimicrobial and antifungal properties, 4-bromo-3-hydroxymethyl-2-methyl phenol is used as an active ingredient in personal care and hygiene products, such as soaps, shampoos, and disinfectants, to provide protection against harmful microorganisms.
Used in Antioxidant and Anti-inflammatory Applications:
4-bromo-3-hydroxymethyl-2-methyl phenol has been studied for its potential use as an antioxidant and anti-inflammatory agent. Its ability to neutralize free radicals and reduce inflammation may contribute to the development of new treatments for various health conditions.
However, it is crucial to handle 4-bromo-3-hydroxymethyl-2-methyl phenol with care, as it may pose environmental or health hazards if not properly used and disposed of. Proper safety measures and regulations should be followed to minimize any potential risks associated with its use.

Upstream product

• 603-80-5 3-hydroxy 2-methylbenzoic acid 
• 54874-26-9 3-hydroxymethyl-2-methylphenol 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 1194700-73-6 5-hydroxy-4-methyl-3H-isobenzofuran-1-one 
• 1255206-70-2 4-methyl-5-[2R-oxiran-2-yl]-2-benzofuran-1(3H)-one 
• 1255206-73-5 trifluoromethanesulfonic acid 4-methyl-1-oxo-1,3-dihydro-isobenzofuran-5-yl ester 
• 1255206-75-7 1,3-dihydro-1-oxo-4-methyl-5-(2-bromoacetyl)isobenzofuran 
• 1255206-69-9 5-ethenyl-4-methyl-2-benzofuran-1(3H)-one 
• 1255206-67-7 5-bromo-4-methyl-2-benzofuran-1(3H)-one 
• 1548289-28-6 (E)-4-methyl-5-(prop-1-en-1-yl)isobenzofuran-1(3H)-one 

Relevant academic research and scientific papers

Bio- And Chemocatalysis for the Synthesis of Late Stage SAR-Enabling Intermediates for ROMK Inhibitors and MK-7145 for the Treatment of Hypertension and Heart Failure

A synthetic strategy to provide two late-stage intermediates for the synthesis of diverse analogues of ROMK inhibitors for the treatment of hypertension and heart failure is described. Key transformations include carbonylation of a bromoarene, regioselect

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Compounds of Formula I and the pharmaceutically acceptable salts thereof are provided as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

This invention relates to compounds of Formula I having the following general structure: [in-line-formulae]Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 [/in-line-formulae] wherein R

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis